Skip to main content

Table 2 Treatment efficacy between ipi3 and HDI by subgroup

From: Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males

Group

HR, 95% CI

OS

RFS

Female gender

0.60 (0.40, 0.92)

0.66 (0.49, 0.89)

In-transit, LN-ve

0.55 (0.29, 1.02)

0.58 (0.38, 0.88)

Ulceration

0.70 (0.50, 0.98)

0.83 (0.65, 1.07)

Stage IIIC

0.67 (0.48, 0.95)

0.78 (0.61, 1.01)

PS = 1

0.55 (0.32, 0.95)

0.74 (0.49, 1.12)

  1. Estimated hazard ratios (HR) with 95% confidence intervals (CI) are provided. The subgroups of female, stage IIIC, PS = 1, ulcerated, in-transit without lymph node involvement demonstrated significant improvement in OS and/or RFS with ipi3 versus HDI. Female gender was significant for both OS and RFS
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us